Abstract: Testosterone replacement therapy is used for the treatment of age-related male hypogonadism, and prostate-specific antigen (PSA) is a primary screening tool for prostate cancer. The systematic review and meta-analysis aimed to determine the effect of testosterone replacement therapy on PSA levels.

Medline, Cochrane Library, EMBASE, and Google Scholar databases were searched until February 28, 2014, and inclusion criteria were as follows: randomized controlled trial; intervention group received testosterone/androgen replacement therapy; control group did not receive treatment; and no history of prostate cancer. The primary outcome was change of PSA level before and after treatment. Secondary outcomes were elevated PSA level after treatment, and the number of patients who developed prostate cancer.

After initially identifying 511 articles, 15 studies with a total of 739 patients that received testosterone replacement and 385 controls were included. The duration of treatment ranged from 3 to 12 months. Patients treated with testosterone tended to have higher PSA levels, and thus a greater change than those that received control treatments (difference in means of PSA levels = 0.154, 95% confidence interval [CI] 0.069 to 0.238, \( P < 0.001 \)). The difference in means of PSA levels were significant higher for patients that received testosterone intramuscularly (IM) than controls (difference in means of PSA levels = 0.271, 95% CI 0.117–0.425, \( P = 0.001 \)). Elevated PSA levels after treatment were similar between patients that received treatment and controls (odds ratio [OR] = 1.02, 95% CI 0.48–2.20, \( P = 0.953 \)). Only 3 studies provided data with respect to the development of prostate cancer, and rates were similar between those that received treatment and controls.

Testosterone replacement therapy does not increase PSA levels in men being treated for hypogonadism, except when it is given IM and even the increase with IM administration is minimal.

INTRODUCTION

Testosterone replacement therapy has become widely accepted for treating age-related and other forms of hypogonadism in men, and is associated with improved mood, increased sexual desire and performance, increased muscle mass and bone mineral density, and improved quality of life.1–6 Prostate cancer is the most commonly diagnosed male cancer, typically in the sixth and seventh decades of life, and the lifetime risk is approximately 16%.7 Screening for prostate cancer includes measurement of prostate-specific antigen (PSA) level and digital rectal examination.8 PSA levels are increased in patients with prostate cancer, and a PSA level \( \geq 4.0 \text{ng/mL} \) is generally considered elevated and a further evaluation, including a biopsy, is typically performed.8 PSA is prostate specific, but not prostate cancer specific, and levels can be altered by medications, benign prostatic hypertrophy (BPH), prostatitis, and urologic manipulations.8

Reducing androgen levels to the castrate range has been clearly shown to reduce prostate cancer growth.9 Conversely, based on early reports, the administration of testosterone was believed to promote prostate cancer growth, and was considered contraindicated in men at risk for prostate cancer.10,11 With the identification of the adverse consequences of low testosterone levels in men with aging, and the benefits of testosterone replacement, the association of prostate cancer and testosterone has been reexamined and current suggests that testosterone replacement is safe with respect to the development of prostate cancer.1,12–15

As PSA is a primary screening tool for prostate cancer, and testosterone replacement therapy is being widely used for the treatment of age-related male hypogonadism, the purpose of this systematic review and meta-analysis was to determine the effect of testosterone replacement therapy on PSA levels in men being treated for hypogonadism.
MATERIALS AND METHODS

Literature Search Strategy

This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. Medline, Cochrane Library, EMBASE, and Google Scholar databases were searched until February 28, 2014, using combinations of the following search terms: testosterone, androgen, prostate cancer, prostatic neoplasms, prostate-specific antigen, PSA, hypogonadism, and gonadal disorders. Reference lists of relevant studies were hand searched. Ethical approval of this study was waived, as systematic review and meta-analyses do not involve patients.

Selection Criteria and Data Extraction

Inclusion criteria were as follows: randomized controlled trial or prospective nonrandomized study; intervention group received testosterone replacement therapy or androgen replacement therapy; control group did not receive testosterone and may have received placebo or conventional treatment; 18 or more years of age; male gender; no history of prostate cancer. Retrospective studies, single-arm studies, those with no numerical data for the outcomes of interest, and letters, comments, case studies, and editorials were excluded. Studies were identified by the search strategy by 2 independent reviewers, and a third reviewer was consulted when disagreement arose.

Data extracted from studies that met the inclusion criteria were the name of the first author, year of publication, study design, demographic data of individuals, dosage and administration of testosterone, and outcomes. Data extraction was performed by 2 independent reviewers, and a third reviewer was consulted for any uncertainties.

Quality Assessment

The methodological quality of each study was assessed using the risk-of-bias assessment tool outlined in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0) by 2 reviewers, and a third reviewer was consulted for any uncertainties.

Outcome Measures and Data Analysis

The primary outcome measure was the change of PSA level between before and after treatment (PSAafter - PSAbefore). The secondary outcomes were the number of patients with an elevated PSA level after treatment, and the number of patients who developed prostate cancer. Data between groups were compared overall, and by route of administration. For the difference of PSA levels between before and after treatment, the difference in means with 95% confidence interval (CI) between testosterone and control treatments was calculated. A difference in means >0 indicates testosterone is favored, which means that testosterone was associated with a greater change in PSA level than control treatment, whereas a difference in means <0 indicates testosterone was associated with a smaller change in PSA level than control treatment. Odds ratios (OR) with 95% CIs were calculated and compared between testosterone and control treatments. An OR >1 indicates testosterone is associated with a higher percentage of patients with an elevated level than control treatment, whereas an OR <1 indicates testosterone is associated with a lower percentage than control treatment.

A χ2-based test of homogeneity was performed using Cochran Q statistic and I2. I2 indicates the percentage of the total variability in effect estimates among trials because of heterogeneity rather than chance. Random-effects models of analysis were used if heterogeneity was detected (P < 0.10, I2 > 50%). Otherwise, fixed-effects models were used. Pooled difference in means and pooled ORs with corresponding 95% CIs were calculated, and a 2-sided P < 0.05 was considered to indicate statistical significance. Sensitivity analysis was carried out for the outcomes using the leave-one-out approach. Publication bias was assessed by constructing a funnel plot and by Egger test. The absence of publication bias is indicated by the data points forming a symmetric funnel-shaped distribution, and a one-tailed significance level >0.05 in Egger test. All analyses were performed using Comprehensive Meta-Analysis statistical software, version 2.0 (Biostat, Englewood, NJ).

RESULTS

Literature Search

A flow diagram of study selection is shown in Figure 1. After initially identifying 511 articles, 430 were excluded and the full texts of 81 were reviewed. Subsequently, 66 were excluded and 15 studies were included in the systematic review and meta-analysis (Table 1).

Study Characteristics and Quality Assessment

Characteristics of the 15 studies included in the meta-analysis are summarized in Table 1, and outcomes are summarized in Table 2. The number of participants that received testosterone treatment ranged from 5 to 237 (total = 739), and the number of participants in the control groups ranged from 5 to 112 (total = 385). In 6 studies, testosterone was administered transdermally, in 7 intramuscularly (IM), and in 2 orally, and the duration of treatment ranged from 3 to 12 months.

The results of the quality assessment of the included studies are shown in Supplemental Figure 1 (http://links.lww.com/MD/A156). Possible performance bias from inappropriate blinding of participants and personnel might be present in 6 studies, and 1 study did not clearly state the blinding process; thus, 53.3% (8/15) of studies had low performance bias (blinding of participants and personnel), and 40.0% (6/15) of studies had high performance bias.

Outcome Measures

Change of PSA Level

Nine of the 15 studies provided complete data regarding PSA levels before and after treatment (Figure 2). In 4 studies, testosterone was administered transdermally, in 4 IM, and in 1 orally. There was no evidence of heterogeneity among the 9 studies (Q statistic = 6.12, I2 = 0%, P = 0.634); thus, a fixed-effects model was used. Overall, patients treated with testosterone tended to have higher PSA levels after treatment, and thus a greater change than those that received control treatments (difference in means of PSA levels = 0.154, 95% CI 0.069–0.238, P < 0.001). The difference in means of PSA levels was significant higher for patients that received testosterone via the IM route than controls (difference in means of PSA levels = 0.271, 95% CI 0.117–0.425, P = 0.001). The difference in means of PSA levels were similar between patients who received testosterone transdermally and controls (difference in means of PSA levels = 0.085, 95% CI: −0.021 to 0.190, P = 0.116).
Elevated PSA Level After Treatment

Seven of the 15 studies provided complete data regarding the number of patients with elevated PSA after treatment; however, 2 studies reported zero patients in the control groups, and thus the 2 studies were excluded from the analysis because zero cannot be used to calculate an OR (Figure 3). In 2 studies, testosterone was administered transdermally, and in 2 IM. In only 1 study was testosterone given orally, and that study included 3 intervention groups and 1 control group. Because the study found no difference in relevant PSA elevations between the 3 treatment groups, we pooled the data of the 3 intervention groups and compared the pooled data with the control group and obtained an OR. There was no evidence of heterogeneity among the 5 studies (Q statistic = 4.16, I² = 3.72%, P = 0.385); thus, a fixed-effects model was used. The rates of elevated PSA levels after treatment were similar between patients that received testosterone and controls (OR = 1.02, 95% CI 0.48–2.20, P = 0.953). The results were similar when the analysis was performed for testosterone given transdermally and IM.

Development of Prostate Cancer

Only 3 studies provided data with respect to the development of prostate cancer (Table 2). Shigehara et al reported no cases of prostate cancer in the testosterone or control groups with a treatment duration of 12 months. Marks et al reported a prostate cancer rate of 9.5% in the testosterone group as compared with a 21.1% rate in the control group with a treatment duration of 12 months.

Sensitivity Analysis

Sensitivity analyses using the leave-one-out approach indicated the direction and magnitude of the combined estimates did not change markedly with the exclusion of individual studies, indicating that the meta-analysis had good reliability (Supplemental Figure 2, http://links.lww.com/MD/A157, http://links.lww.com/MD/A158).

Publication Bias

Funnel plot symmetry and Egger test indicated there was no publication bias for either PSA level change between before and after treatment or elevated PSA level after treatment (Supplemental Figure 3, http://links.lww.com/MD/A159, http://links.lww.com/MD/A160).

DISCUSSION

The results of this meta-analysis showed that testosterone replacement was not associated with an increase in PSA level, although a slight increase was seen when testosterone was given...
| First author | Study Design | Diagnosis | Testosterone Treatment | Control |
|--------------|--------------|-----------|------------------------|---------|
|              |              |           | Number of patients | Age (year) | Dose/Frequency | Number of patients | Age (year) | Type of control | Duration | Route |
| Kaufman18    | RCT          | Hypogonadal men | 170 | 52.9 ± 9.6 | 1.62% testosterone gel | 26 | 55.8 ± 10.8 | Placebo |
| Bauman19     | Prospective, nonrandomized, placebo controlled | Hypogonadal men with spinal cord injury | 11 | 43 ± 6 | Testosterone patch 5 mg/day | 11 | 35 ± 9 | Control |
| Jones20      | RCT          | Hypogonadal men with type 2 DM and/or metabolic syndrome | 108 | 59.9 ± 9.1 | 2% testosterone gel; q.d. | 112 | 59.9 ± 9.4 | Placebo |
| Shigehara21  | RCT          | Hypogonadal men with benign prostate hypertrophy | 23 | 72.0 ± 6.5 | Testosterone enanthate 250 mg; every 4 weeks | 23 | 68.9 ± 9.1 | Placebo |
| Gopal22      | RCT          | Hypogonadal men with type 2 DM | 11 | 44.23 ± 3.29 | Testosterone 200 mg; every 15 days | 11 | NA | Placebo |
| Andrade2     | RCT          | Hypogonadal men | 17 | 70.6 ± 6.1 | Testosterone cypionate 200 mg; every 3 weeks | 14 | NA | Hypogonadal males, no testosterone (n = 14) + nonhypogonadal controls (n = 31) |
| Chiang23     | RCT          | Hypogonadal men | 20 | Range (20–75) | 1% testosterone gel; q.d. | 20 | NA | Placebo |
| Legros24     | RCT          | Hypogonadal men | 78 | 59.5 ± 6.5 | Testosterone undecanoate 80 mg/day | 79 | 58.4 ± 5.5 | Placebo |
|              | RCT          | Hypogonadal men | 82 | 58.4 ± 5.7 | Testosterone undecanoate 80 mg; b.i.d. (160 mg/day) | 82 | 58.6 ± 5.7 | Placebo |
|              | RCT          | Hypogonadal men | 77 | 58.6 ± 5.7 | Testosterone undecanoate 80 mg; TID (240 mg/day) |
| Marks25      | RCT          | Hypogonadal men | 21 | Median 68, Range (44, 78) | Testosterone enanthate 150 mg; every 2 weeks | 19 | Median 70, Range (45, 78) | Placebo |
| Merza26      | RCT          | Borderline hypogonadal men | 20 | 63 ± 9 | Testosterone patch 5 mg/day | 19 | 59.7 ± 10.2 | Placebo |
| Okun27       | RCT          | Parkinson disease | 15 | 66.7 ± 10.26 | Testosterone enanthate 200 mg; every 2 weeks | 15 | 69.9 ± 9.41 | Placebo |
| Park4        | Prospective, nonrandomized, placebo controlled study | Men with primary hypogonadism or andropause with sexual dysfunction | 33 | NA | Testosterone undecanoate 80 mg; b.i.d. (160 mg/day) | 6 | NA | Placebo |
| Tan28        | RCT          | Hypogonadal men with Alzheimer disease | 5 | Mean 72.4, Range (68, 80) | Testosterone enanthate 200 mg; every 2 weeks | 5 | Mean 68.9, Range (67, 82) | Placebo |
| Bhasin29     | RCT          | Hypogonadal men with HIV infection | 20 | range (18, 60) | Testosterone patch 5 mg/day | 21 | NA | Placebo |
| Sih30        | RCT          | Hypogonadal men | 17 | 65 ± 7 | Testosterone cypionate 200 mg; every 14–17 days | 15 | 68 ± 6 | Placebo |

Data reported as mean ± standard deviation unless otherwise indicated. RCT = randomized controlled trial; DM = diabetes mellitus; HIV = human immunodeficiency virus; IM = intramuscular; PO = oral/per os; NA = not available.
TABLE 2. Clinical Outcomes (PSA Levels and Elevated PSA Concentrations) of Included Studies

| First Author | Route | Treatments | Number of Patients Evaluated (PSA Level Change) | PSA Level (ng/mL) Pre- (median) | Number of Patients Evaluated (PSA Level Post-Treatment) | Number of Patients With Elevated PSA Level | Number of Newly Developed Prostate Cancers |
|--------------|-------|------------|-----------------------------------------------|---------------------------------|--------------------------------------------------------|-------------------------------------------|------------------------------------------|
| Kaufman18    | Transdermal | Testosterone    | 191 NA                                    | 191 10 (5.2%)                  | 191 10 (5.2%)                                          | NA                                       | NA                                       |
| Control 28   | NA                                    | 28 NA                                    | 28 3 (10.7%)                  | 28 3 (10.7%)                                          | NA                                       | NA                                       |
| Bauman19     | Transdermal | Testosterone 11 | 0.9 (0.7) ↓ 1.1 (0.8) | NA NA | NA NA | NA NA | NA NA |
| Control 11   | NA                                    | 1.3 (1.0) ↓ 1.3 (0.6) | NA NA | NA NA | NA NA | NA NA |
| Jones30      | Transdermal | Testosterone 88 | 1.50 (1.80) ↓ 1.41 (1.29) | NA NA | NA NA | NA NA | NA NA |
| Control 92   | NA                                    | 1.19 (1.18) ↓ 1.18 (1.17) | NA NA | NA NA | NA NA | NA NA |
| Shigehara21  | IM   | Testosterone 23 | 1.055 ± 0.531 ↓ 1.377 ± 0.756 | 23 1 (4.3%) 0 (0%) | 23 0 (0%) 0 (0%) | NA NA | NA NA |
| Control 23   | NA                                    | 1.662 ± 0.531 ↓ 1.336 ± 1.050 | 23 0 (0%) 0 (0%) | 23 0 (0%) 0 (0%) | NA NA | NA NA |
| Gopal22      | IM   | Testosterone 11 | NA                                    | 11 0 (0%)                  | 11 0 (0%) | NA NA | NA NA |
| Control 9    | NA                                    | NA                                    | 9 0 (0%)                          | 9 0 (0%) | 9 0 (0%) | NA NA | NA NA |
| Andrade3     | IM   | Testosterone 17 | 1.29 (0.7) ↓ 1.89 (1.5) | NA NA | NA NA | NA NA | NA NA |
| Control 14   | NA                                    | 3.26 (3.89) ↓ 2.31 (3.01) | NA NA | NA NA | NA NA | NA NA |
| Healthy control 31 | 2.38 (4.27) ↓ 2.89 (5.39) | NA NA | NA NA | NA NA | NA NA | NA NA |
| Chiang23     | Transdermal | Testosterone 20 | change: 0.074 (0.208) | 20 0 (0%) | 20 0 (0%) | NA NA | NA NA |
| Control 20   | change: -0.069 (0.436) | NA NA | NA NA | NA NA | NA NA | NA NA |
| Legros24     | PO   | Testosterone 80 mg/day | 78 Pre-treatment all < 4 | 78 5 (6.5%) 1 (1.3%) | 78 5 (6.5%) 1 (1.3%) | NA NA | NA NA |
| Testosterone 160 mg/day | 82 | 3 (3.8%) | 0 (0%) | 82 3 (3.8%) 0 (0%) | NA NA | NA NA |
| Testosterone 240 mg/day | 77 | 4 (5.3%) | 0 (0%) | 77 4 (5.3%) 0 (0%) | NA NA | NA NA |
| Control 79   | NA                                    | 92 1.19 (1.17) | 1.19 (1.17) | 92 1.19 (1.17) | NA NA | NA NA |
| Marks25      | IM   | Testosterone 21 | change: 0.90 (0.89) | 21 NA | 21 NA | NA NA | NA NA |
| Control 19   | change: 0.60 (1.55) | 19 NA | 19 NA | 19 NA | 19 NA | NA NA |
| Merza26      | Transdermal | Testosterone 20 | NA                                    | 20 5 (25%)                  | 20 5 (25%) | NA NA | NA NA |
| Control 19   | NA                                    | NA                                    | 19 1 (6%)                           | 19 1 (6%) | 19 1 (6%) | NA NA | NA NA |
| Okum27       | IM   | Testosterone 15 | NA                                    | 15 1 (3.3%)                  | 15 1 (3.3%) | NA NA | NA NA |
| Control 15   | NA                                    | NA                                    | 15 1 (3.3%)                           | 15 1 (3.3%) | 15 1 (3.3%) | NA NA | NA NA |
| Park4        | PO   | Testosterone 33 | 0.7 (0.4) ↓ 0.7 (0.4), n = 29 | NA NA | NA NA | NA NA | NA NA |
| Control 6    | 0.6 (0.4) ↓ 0.9 (0.3), n = 6 | NA NA | NA NA | NA NA | NA NA | NA NA |
| Tan28        | Transdermal | Testosterone 5 | 0.98 ↓ 1.37 | 5 NA | 5 NA | NA NA | NA NA |
| Control 5    | NA                                    | NA                                    | NA NA | NA NA | NA NA | NA NA |
| Bhasin29     | Transdermal | Testosterone 14 | change: 0.05 ± 0.04 | 20 0 (0%) | 20 0 (0%) | NA NA | NA NA |
| Control 18   | change: -0.01 ± 0.24 | 21 0 (0%) | 21 0 (0%) | 21 0 (0%) | 21 0 (0%) | NA NA | NA NA |
| Sih30        | IM   | Testosterone 10 | change: 0.7 ± 0.2 | 10 NA | 10 NA | NA NA | NA NA |
| Control 12   | change: 0.4 ± 0.2 | 12 NA | 12 NA | 12 NA | 12 NA | NA NA | NA NA |

IM = intramuscular, PO = oral/per os, NA = not available.

*Bhasin29 used different data sets for evaluating different outcomes. For PSA level, 32 patients were evaluated. For the number of patients with elevated PSA level and the number of patients who developed prostate cancer, 41 patients were evaluated.

IM. Although only 3 of the 15 studies reported the incidence of prostate cancer, there was no difference between the treatment and control groups in the 3 studies.

Early studies suggested that the administration of testosterone could promote prostate cancer growth,10,11 and later studies showed that reducing androgen levels to the castrate range reduced prostate cancer growth.9 These data led to the supposition that raising serum testosterone levels with replacement therapy could cause an occult prostate tumor to grow into an aggressive lesion.13 Current data, however, indicate that variations of testosterone levels within the physiological range have little, if any, impact on prostate cancer growth. A low testosterone level may be associated with a high-risk for developing prostate cancer, and that normal testosterone levels play a protective role against prostate cancer.13,14,31–33

Of the studies included in this meta-analysis, the earliest was performed in 1997 by Sih et al,30 who studied hypogonadal men with a mean age of 68 years and reported that testosterone supplementation (200 mg testosterone cypionate biweekly for 12 months) improved strength, increased hemoglobin levels, and lowered leptin levels. Andrade et al2 also treated hypogonadal men with IM testosterone for 6 months and reported an improvement in body composition. Chiang et al23 and Park et al4 both reported that testosterone replacement improved quality of life and sexual function in men with testosterone deficiency. In one of the larger studies included in the current analysis, Legros et al24 examined the effect of oral testosterone undecanoate in men with symptomatic hypogonadism in a multicenter, randomized, double-blind, placebo-controlled trial and found that testosterone replacement did not improve the total Aging Males’ Symptom score after 6 months of treatment, except in the sexual symptom subdomain were a modest improvement seen with a dose of 160 mg/day. In other included studies, Bauman et al19 reported that transdermal testosterone improved lean tissue mass in men with spinal cord injuries, and Merza et al26 found that transdermal testosterone increased lean body mass and decreased bone absorption in men with borderline hypogonadism. Interestingly, 2 of the included studies examined the effect of testosterone replacement in men with type 2 diabetes mellitus and whereas one22 found that IM testosterone did not have an effect on insulin resistance or dyslipidemia, the other20 showed that transdermal replacement
had a beneficial effect on insulin resistance and lipid levels. Importantly, Marks et al. showed that 6 months of IM testosterone enanthate normalized serum testosterone levels and had little effect on prostate tissue androgen levels or function.

With respect to PSA levels, although not included in the meta-analysis, El-Sakka et al. showed no significant change in PSA level after 1 year of testosterone replacement in hypogonadal men with erectile dysfunction, with other studies reporting similar findings. Coward et al. showed that PSA levels remained stable after administration of testosterone for replacement therapy was no greater than that of the general population. The contradiction that androgen deprivation can markedly reduce the growth of prostate cancer while administration of testosterone replacement does not affect prostate cancer incidence or growth has been addressed by the saturation model. The model is based on the observation that the prostate is very sensitive to changes in androgens at low concentrations, which is a plateau at which further increases in androgen concentrations elicit no additional response from the prostate.

A primary limitation of this study is the heterogeneity of the studies including the populations examined, testosterone replacement regimes, dosages, and length of therapy, and

### FIGURE 2
Forest plot comparing PSA level change between patients receiving testosterone treatment via transdermal, oral (PO) and intramuscular (IM) routes versus control treatments. CI = confidence interval, Lower limit = lower bound of the 95% CI; Upper limit = upper bound of the 95% CI.

### FIGURE 3
Forest plot comparing the number of patients with elevated PSA level after treatment via transdermal, oral (PO) and intramuscular (IM) routes versus control treatments. CI = confidence interval, Lower limit = lower bound of the 95% CI, Upper limit = upper bound of the 95% CI.
baseline PSA levels. In addition, data in the studies included were not sufficient to estimate the risk of developing prostate cancer.

CONCLUSION

The results of this study indicate that testosterone replacement therapy does not increase PSA levels in men being treated for hypogonadism, except when it is given IM and even the increase with IM administration is minimal. Data of the included studies were not sufficient to evaluate the risk of prostate cancer with testosterone replacement therapy; however, based on evidence in the literature it does not appear that the risk of prostate cancer is affected by testosterone replacement therapy.

REFERENCES

1. Kava BR. To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer. Curr Urol Rep. 2014;15:422.

2. Andrade ES Jr, Claupach R, Bukmsan S. Short term testosterone replacement therapy improves libido and body composition. Arq Bras Endocrinol Metabol. 2009;53:996–1004.

3. Miner MM, Bhattacharya RK, Blick G, et al. 12-month observation of testosterone replacement effectiveness in a general population of men. Postgrad Med. 2013;125:8–18.

4. Park NC, Yan BQ, Chung JM, Lee KM. Oral testosterone undecanoate (Androil) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male. 2003;6:86–93.

5. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085–2098.

6. Yamaguchi K, Ishikawa T, Chiba K, Fujisawa M. Assessment of possible effects for testosterone replacement therapy in men with symptomatic late-onset hypogonadism. Andrologia. 2011;43:52–56.

7. Wright JL, Lange PH. Newer potential biomarkers in prostate cancer. Rev Urol. 2007;9:207–213.

8. Obort AS, Ajadi MB, Akinloye O. Prostate-specific antigen: any successor in sight? Rev Urol. 2013;15:97–107.

9. Mathew P. The bifunctional role of steroid hormones: implications for therapy in prostate cancer. Oncology (Williston Park). 2014;28:397–404.

10. Fowler JE Jr, Whitemore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126:372–375.

11. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168:9–12.

12. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50:935–939.

13. Morgentaler A. Testosterone and prostate cancer: what are the risks for middle-aged men? Urol Clin North Am. 2011;38:119–124.

14. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–320.

15. Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190:639–644.

16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–W94.

17. Higgins JPT, Green S (Eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. 0. The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org. Accessed June 30, 2014.

18. Kaufman JM, Miller MG, Fitzpatrick S, et al. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. J Sex Med. 2012;9:1149–1161.

19. Bauman WA, Cirmigliano CM, La Fountaine MF, et al. A small-scale clinical trial to determine the safety and efficacy of testosterone replacement therapy in hypogonadal men with spinal cord injury. Horm Metab Res. 2011;43:574–579.

20. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabet Care. 2011;34:828–837.

21. Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hyperplasty: a randomised controlled study. Aging Male. 2011;14:53–58.

22. Gopal RA, Botha N, Acharya SV, et al. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract. 2010;16:570–576.

23. Chiang HS, Cho SL, Lin YC, Hwang TI. Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology. 2009;73:762–766.

24. Legros JJ, Meuleman EJ, Elbers JM, et al. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol. 2009;160:821–831.

25. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351–2361.

26. Merza Z, Blumsohn A, Mah PM, et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl. 2006;29:381–391.

27. Okun MS, Fernandez HH, Rodriguez RL, et al. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study. Arch Neurol. 2006;63:729–735.

28. Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s disease. Aging Male. 2003;6:13–17.

29. Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab. 1998;83:3155–3162.

30. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661–1667.

31. Barqawi A, Crawford ED. Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Int J Impot Res. 2006;18:323–328.

32. Endogenous Hormones Prostate Cancer Collaborative GroupRoddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–183.
33. Cui Y, Zong H, Yan H, et al. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis.* 2014;17:132–143.

34. El-Sakka AI, Hassoba HM, Elbakry AM, et al. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. *J Sex Med.* 2005;2:235–240.

35. Raynaud JP, Gardette J, Rollet J, et al. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. *BJU Int.* 2013;111:880–890.

36. Bhattacharya RK, Khera M, Blick G, et al. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). *Clin Interv Aging.* 2012;7:321–330.

37. Coward RM, Simhan J, Carson CC 3rd. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. *BJU Int.* 2009;103:1179–1183.